YU64301A - Derivati kamptotecina koji imaju antitumorno dejstvo - Google Patents

Derivati kamptotecina koji imaju antitumorno dejstvo

Info

Publication number
YU64301A
YU64301A YU64301A YUP64301A YU64301A YU 64301 A YU64301 A YU 64301A YU 64301 A YU64301 A YU 64301A YU P64301 A YUP64301 A YU P64301A YU 64301 A YU64301 A YU 64301A
Authority
YU
Yugoslavia
Prior art keywords
antitumor activity
derivatives
camptothechin
formula
compounds
Prior art date
Application number
YU64301A
Other languages
English (en)
Inventor
Sergio Penco
Lucio Merlini
Franco Zunino
Paolo Carminati
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Instituto Nazionale Per Lo Studio E La Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A., Instituto Nazionale Per Lo Studio E La Cura Dei Tumori filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of YU64301A publication Critical patent/YU64301A/sh
Publication of RS50405B publication Critical patent/RS50405B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Otkriveni su derivati kamptotecina koji imaju opštu formulu (I), u kojoj su R1, R2 i R3 kao što je definisano u opisu. Jedinjenja formule (I) imaju antitumorno dejstvo i pokazuju dobar terapeutski indeks. Postupci za dobijanje jedinjenja formule (I) i njihova upotreba u dobijanju medikamenata korisnih u lečenju tumora, virusnih infekcija i antiplazmodijum falciparum je takodje otkrivena.[Camptothecin derivatives of camptothecin of formula (I), wherein the groups R1, R2 and R3 are as defined in the description are disclosed. The compounds of formula (I) are endowed with antitumor activity and show a good therapeutic index. Processes for the preparation of the compounds of formula (I) and their use in the preparation of medicaments useful in the treatment of tumors, viral infections and antiplasmodium falciparum are also disclosed.
YUP-643/01A 1999-03-09 2000-03-08 Derivati kamptotecina koji imaju antitumorno dejstvo RS50405B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99830124A EP1044977B1 (en) 1999-03-09 1999-03-09 Camptothecin derivatives having antitumor activity

Publications (2)

Publication Number Publication Date
YU64301A true YU64301A (sh) 2005-07-19
RS50405B RS50405B (sr) 2009-12-31

Family

ID=8243303

Country Status (39)

Country Link
US (2) US6242457B1 (sh)
EP (1) EP1044977B1 (sh)
JP (1) JP4610743B2 (sh)
KR (1) KR100702085B1 (sh)
CN (1) CN1139592C (sh)
AR (1) AR022860A1 (sh)
AT (1) ATE216998T1 (sh)
AU (1) AU774174B2 (sh)
BG (1) BG65032B1 (sh)
BR (1) BR0008840B1 (sh)
CA (1) CA2362760C (sh)
CO (1) CO5180590A1 (sh)
CZ (1) CZ304465B6 (sh)
DE (1) DE69901379T2 (sh)
DK (1) DK1044977T3 (sh)
EA (1) EA003605B1 (sh)
EE (1) EE04679B1 (sh)
EG (1) EG23999A (sh)
ES (1) ES2175919T3 (sh)
HK (1) HK1031222A1 (sh)
HR (1) HRP20010667B1 (sh)
HU (1) HU229506B1 (sh)
IL (2) IL144958A0 (sh)
IS (1) IS2003B (sh)
ME (2) ME00017B (sh)
MX (1) MXPA01009081A (sh)
NO (1) NO328363B1 (sh)
NZ (1) NZ513393A (sh)
PE (1) PE20001485A1 (sh)
PL (1) PL222208B1 (sh)
PT (1) PT1044977E (sh)
RS (1) RS50405B (sh)
SI (1) SI1044977T1 (sh)
SK (1) SK287561B6 (sh)
TN (1) TNSN00045A1 (sh)
TR (1) TR200102603T2 (sh)
TW (1) TWI272272B (sh)
WO (1) WO2000053607A1 (sh)
ZA (1) ZA200107408B (sh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4790911B2 (ja) 1999-01-13 2011-10-12 アルケミア オンコロジー ピーティワイ リミテッド 薬物の効力を増強するための組成物および方法
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
FR2794123B1 (fr) * 1999-05-28 2001-07-27 Aventis Pharma Sa Preparation de derives de la camptothecine et de la nothapodytine
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US20040029906A1 (en) * 2001-07-31 2004-02-12 Michael Christman Inhibitors of dna polymerase sigma
US20050042303A1 (en) * 2001-08-27 2005-02-24 Brown Tracey Jean Therapeutic protocols
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
ITRM20020305A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Camptotecine con anello lattonico modificato.
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITRM20030344A1 (it) * 2003-07-14 2005-01-15 Ist Naz Stud Cura Dei Tumori 7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi.
RU2006137657A (ru) * 2004-03-26 2008-05-10 Новартис АГ (CH) Применение производных камптотецина для лечения пролиферативных заболеваний с использованием схемы лечения с фиксированной дозой
JP5170741B2 (ja) 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
ITRM20040242A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine.
ITRM20040241A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 20 con antagonisti delle integrine.
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
CN100334089C (zh) * 2004-07-21 2007-08-29 王洋 一种9-硝基喜树碱的生产方法
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
PL1827437T3 (pl) 2004-12-15 2013-06-28 Sigma Tau Ind Farmaceuti Połączenia środków terapeutycznych do leczenia raka
CA2590756C (en) * 2004-12-21 2014-09-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Stereoselective process and crystalline forms of a camptothecin
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
AU2006270297B2 (en) 2005-07-14 2013-01-17 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
AU2006274509B2 (en) * 2005-07-27 2012-01-19 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
CA2617873A1 (en) * 2005-08-10 2007-02-15 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
EA013877B1 (ru) * 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
PL1962850T3 (pl) * 2005-12-21 2012-07-31 Sigma Tau Ind Farmaceuti Leczenie lekoopornych nowotworów
EP1989212B1 (en) 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
EP1998809B1 (en) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
AU2008210511A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
EP2120948A1 (en) * 2007-02-13 2009-11-25 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
CN101784277A (zh) * 2007-08-01 2010-07-21 希格马托制药工业公司 儿科肿瘤的治疗
EP2096113A1 (en) * 2008-02-05 2009-09-02 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. 9-substituted camptothecin derivatives as antitumor compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
KR20180058759A (ko) 2015-09-25 2018-06-01 제트와이 테라퓨틱스 인코포레이티드 폴리사카라이드-비타민 접합체를 포함하는 미립자를 기재로 하는 약물 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
DE69233169T2 (de) * 1991-11-15 2004-05-27 Smithkline Beecham Corp. Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
GB9512670D0 (en) * 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
BR9711319B1 (pt) * 1996-08-19 2009-08-11 derivados de camptotecina altamente lipofìlicos.

Also Published As

Publication number Publication date
CZ304465B6 (cs) 2014-05-21
IL144958A (en) 2009-08-03
ES2175919T3 (es) 2002-11-16
DK1044977T3 (da) 2002-07-08
CO5180590A1 (es) 2002-07-30
EA200100954A1 (ru) 2002-04-25
MEP4008A (xx) 2010-02-10
EE200100466A (et) 2002-12-16
SK11642001A3 (sk) 2002-01-07
AU3160400A (en) 2000-09-28
US6589939B2 (en) 2003-07-08
NO328363B1 (no) 2010-02-01
PT1044977E (pt) 2002-09-30
HU229506B1 (en) 2014-01-28
PL222208B1 (pl) 2016-07-29
MXPA01009081A (es) 2002-08-30
AR022860A1 (es) 2002-09-04
CN1139592C (zh) 2004-02-25
CZ20013077A3 (cs) 2002-01-16
TWI272272B (en) 2007-02-01
CA2362760C (en) 2009-08-18
CN1343209A (zh) 2002-04-03
NO20014128D0 (no) 2001-08-24
PL355094A1 (en) 2004-03-22
ZA200107408B (en) 2002-05-29
SK287561B6 (sk) 2011-02-04
BG105810A (en) 2002-06-28
EG23999A (en) 2008-03-19
ATE216998T1 (de) 2002-05-15
IS6031A (is) 2001-07-31
WO2000053607A1 (en) 2000-09-14
EE04679B1 (et) 2006-08-15
IL144958A0 (en) 2002-06-30
BR0008840A (pt) 2002-01-08
NO20014128L (no) 2001-08-24
KR20010102519A (ko) 2001-11-15
HRP20010667B1 (en) 2003-06-30
HUP0200210A2 (hu) 2002-05-29
RS50405B (sr) 2009-12-31
HUP0200210A3 (en) 2004-03-29
JP4610743B2 (ja) 2011-01-12
ME00017B (me) 2010-06-10
DE69901379D1 (de) 2002-06-06
US6242457B1 (en) 2001-06-05
EP1044977B1 (en) 2002-05-02
HK1031222A1 (en) 2001-06-08
TR200102603T2 (tr) 2002-01-21
KR100702085B1 (ko) 2007-04-02
TNSN00045A1 (fr) 2005-11-10
PE20001485A1 (es) 2000-12-07
HRP20010667A2 (en) 2002-08-31
JP2002539128A (ja) 2002-11-19
EA003605B1 (ru) 2003-06-26
DE69901379T2 (de) 2002-11-07
IS2003B (is) 2005-04-15
BG65032B1 (bg) 2006-12-29
AU774174B2 (en) 2004-06-17
SI1044977T1 (en) 2002-08-31
US20010008939A1 (en) 2001-07-19
NZ513393A (en) 2003-04-29
EP1044977A1 (en) 2000-10-18
BR0008840B1 (pt) 2011-12-27
CA2362760A1 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
YU64301A (sh) Derivati kamptotecina koji imaju antitumorno dejstvo
MY140398A (en) 4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
GEP20022653B (en) Processes and Intermediates for Preparing Anti-Cancer Compounds
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
GEP20063799B (en) Tropane derivatives useful in therapy
AP1853A (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents.
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
ZA200110540B (en) Novel diphenyl-piperidine derivate.
CY1108890T1 (el) 7-ιμινο παραγωγα καμπτοθεκινης που εχουν αντιογκικη δραση
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
PT1095040E (pt) Novos benzoxazoles com actividade inibidora da pde
AU2162202A (en) Antitumor therapy comprising distamycin derivatives
MXPA03003798A (es) Derivados triciclicos de indol con actividad antiangiogenica.
CA2362697A1 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, method for producing them and their use as medicaments
MXPA04003173A (es) Compuestos policiclicos que tienen actividad antituoral.
YU30602A (sh) Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima
TH52587B (th) อนุพันธ์แคมพ์โทเธซินซึ่งมีฤทธิ์ต่อต้านเนื้องอก
WO2002057286A3 (en) 9-amino erythromycin derivatives with antibacterial activity
EP1724270A3 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
WO2001000240A3 (en) Antitumor compound